Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for MARK HAHN´┐Ż
+0.08 (1.77%)
After Hours: 4.61 0.00 (0.00%)
Feb 12, 5:07PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.48 - 4.68
52 week 4.07 - 15.01
Open 4.64
Vol / Avg. 6.25M/9.45M
Mkt cap 1.21B
P/E     -
Div/yield     -
EPS -0.43
Shares 269.86M
Beta 1.43
Inst. own 73%
Feb 24, 2016
Q4 2015 Novavax Inc Earnings Release (Estimated) Add to calendar
Jan 13, 2016
Novavax Inc at JPMorgan Healthcare Conference
Dec 15, 2015
Novavax Inc at Guggenheim Boston Healthcare Conference
Dec 1, 2015
Novavax Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 17, 2015
Novavax Inc at Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -507.59% -270.55%
Operating margin -508.80% -272.97%
EBITD margin - -255.03%
Return on average assets -32.04% -32.46%
Return on average equity -35.21% -38.33%
Employees 308 -
CDP Score - -


20 Firstfield Rd
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 52
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 61
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 51
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 55
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 55
Bio & Compensation  - Reuters
Chris Dunne Vice President - Finance
Bio & Compensation  - Reuters
Mark C. Twyman Vice President of Marketing
Bio & Compensation  - Reuters
Jody Lichaa Vice President - Quality Assurance
Bio & Compensation  - Reuters